# Gilead Sciences, Inc. – Consensus ‘buy’ rating and 8.2% Upside Potential

- Link: https://www.directorstalkinterviews.com/gilead-sciences-inc-consensus-buy-rating-and-8-2-upside-potential/4121184029
- Published: 2025-01-17T14:35:56+00:00
- Author: Charlotte Edwards

**Gilead Sciences, Inc.** which can be found using ticker (GILD) have now 26 analysts
in total covering the stock. The consensus rating is pointing to ‘buy’. The target
price High/Low ranges between $125.00 and $73.00 calculating the average target 
price we see $99.96. Given that the stocks previous close was at $92.38 this indicates
there is a potential upside of 8.2%. It’s also worth noting that there is a 50 day
moving average of $91.88 and the 200 day MA is $78.43. The market cap for the company
is 114.22B. Currently the stock stands at: $91.65 USD

 The potential market cap would be $123,590,819,597 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 1018.33, revenue per share of $22.70
and a 11.96% return on assets.

Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in 
advancing medicines to prevent and treat life-threatening diseases, including human
immunodeficiency virus (HIV), viral hepatitis and cancer. The Company offers products
in HIV, Onocolgy, Liver Disease, Vekulaery, and Other. Under HIV, it offers Biktarvy,
Complera/Eviplera, Genvoya, Odefsey, Stribild, and Truvada. Its Veklury (remdesivir)
is a nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus
disease 2019 (COVID-19). Under oncology it offers cell therapy containing Tecartus
and Yescarta. Under this Liver Disease consists of Chronic hepatitis C virus (HCV)(
Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir) and Chronic hepatitis B virus (
HBV) / hepatitis delta virus (HDV) (Vemlidy and Viread). The Company’s other products
include AmBisome and Letairis. It also operates a portfolio of small molecule inhibitors
targeting PARP1 for oncology and MK2 for inflammatory diseases.

Share on: